8 results on '"Lad, Deepesh"'
Search Results
2. Adolescent and Young Adult Chronic Myeloid Leukemia in Real-World Settings: Experience from a Tertiary Care Institute in Northern India.
- Author
-
Yanamandra, Uday, Sahu, Kamal Kant, Karunakaran, Parathan, Katoch, Deeksha, Jain, Nidhi, Khadwal, Alka, Prakash, Gaurav, Lad, Deepesh, Naseem, Shano, Varma, Neelam, Varma, Subhash, and Malhotra, Pankaj
- Subjects
MYELOFIBROSIS ,TREATMENT of chronic myeloid leukemia ,CHRONIC myeloid leukemia ,CYTOGENETICS ,RETROSPECTIVE studies ,TERTIARY care ,PROGNOSIS ,DIAGNOSIS - Abstract
The data on adolescent and young adult chronic myeloid leukemia (AYA-CML) from the Indian subcontinent are scarce. We studied characteristics of AYA-CML through a retrospective analysis of 1950 CML patients registered to a tertiary care hospital in Northern India. AYA-CML represented 22.1% of all CML patients, with cumulative overall survival (OS) of 84%, and 1 and 8 years OS of 94.2% and 74.2%, respectively. Of all cases, 8.91% patients had advanced disease at the time of diagnosis, and 13.95% had myelofibrosis in the diagnostic marrow, 79.6% had complete cytogenetic response (CCyR), and 84.5% had major molecular response (MMR). Loss of CCyR and MMR was noted in 37.2% and 28.4%, respectively. The cumulative OS was significantly better in patients on patient assistance program, and they were initiated on therapy within 3 months of symptom onset. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. Long‐term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients.
- Author
-
Vinay, Keshavamurthy, Yanamandra, Uday, Dogra, Sunil, Handa, Sanjeev, Suri, Vikas, Kumari, Savita, Khadwal, Alka, Prakash, Gaurav, Lad, Deepesh, Varma, Subhash, and Malhotra, Pankaj
- Subjects
DRUG side effects ,IMATINIB ,CHRONIC myeloid leukemia ,CROSS-sectional method ,HYPERPIGMENTATION ,SKIN diseases - Abstract
Abstract: Background: Short‐term mucocutaneous adverse effects are well documented with imatinib. However, studies on long‐term adverse effects and in the ethnic population are lacking. Objective: To study the long‐term mucocutaneous adverse effects of imatinib and factors predicting these adverse effects. Methods: In this cross‐sectional study, consenting adult chronic myeloid leukemia patients on imatinib for more than 250 days were recruited. The details of imatinib treatment were retrieved from hematology clinic records. Results: Four hundred and thirty‐eight patients who were on imatinib for a mean duration of 1820 days were recruited. A mean number of 1.42 ± 0.98 cutaneous adverse effects were seen per patient. Melasma‐like pigmentation, periorbital edema, oral lichenoid reaction, cutaneous hypopigmentation, and vesicobullous eruptions were seen in 236 (53.9%), 81 (18.5%), 70 (16%), 42 (9.6%), and 12 (2.7%) patients, respectively. Drug‐induced cutaneous eruptions (9.1%) and cutaneous hypopigmentation (9.6%) were seen less frequently. Cutaneous hyperpigmentation was more likely seen in younger patients (
P = 0.001) and females (P < 0.001). On multivariate analysis, female gender was a significant risk factor for developing cutaneous hyperpigmentation and periorbital edema. Conclusion: Cutaneous hyperpigmentation and periorbital edema are common long‐term adverse effects of imatinib in Indian patients. Female gender is a significant risk factor for the development of both these adverse effects. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
4. Variation in Adherence Measures to Imatinib Therapy.
- Author
-
Yanamandra, Uday, Malhotra, Pankaj, Sahu, K.K., Sushma, Yanamandra, Saini, Neha, Chauhan, Pooja, Gill, Jasmeen, Rikhi, Deepika, Khadwal, Alka, Prakash, Gaurav, Lad, Deepesh, Suri, Vikas, Kumari, Savita, Varma, Neelam, and Varma, Subhash
- Subjects
IMATINIB ,CHRONIC myeloid leukemia ,CROSS-sectional method ,STATISTICS ,MULTIVARIATE analysis - Abstract
Purpose The introduction of tyrosine kinase inhibitors has transformed the care of patients with chronic myeloid leukemia, with survival approaching that of healthy individuals. Current-day challenges in chronic myeloid leukemia care include adherence to tyrosine kinase inhibitor therapy.Westudied adherence from resource-constrained settings and tried to analyze the factors responsible for nonadherence in these individuals. We also correlated adherence to current molecular status. Patients and Methods This was a single-center, cross-sectional, observational study from north India. It consisted of a questionnaire-based survey in which a one-to-one interview technique was used by trained nursing staff administering the Modified Morisky Adherence Scale (MMAS-9) questionnaire. Adherence was also measured on the basis of physician’s assessment. JMP 13.0.0 was used for statistical analysis. Results A total of 333 patients with a median age of 42 years were included in the study. The median BCRABL/ ABL ratio (IS) was 0.175 (0.0 to 98.0). The mean MMAS-9 score was 1162. Adherence was seen in 54.95% on the basis of MMAS-9, whereas physician’s assessment reported adherence in 90.39% of patients. Using the x
2 test, no relationship was found between the two assessment techniques. There was a significant relationship between major molecular response status and adherence by physician’s assessment and MMAS-9 (P < .001). Bivariate analysis by logistic fit showed a good relation between the MMAS-9 score and the BCR-ABL/ABL ratio (IS), x2 (1,220) = 135.45 (P < .001). On multivariate analysis, enrolment in the Novartis Oncology Access program (a patient assistance program) was significantly associated with adherence (P = .012). Conclusion This study highlights the lack of adherence in real-world settings and the various factors responsible. Such studies are important from a public health services perspective in various settings around the world because they may lead to corrective action being taken at the institutional level. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
5. Variation in Adherence Measures to Imatinib Therapy.
- Author
-
Yanamandra, Uday, Malhotra, Pankaj, Sahu, K.K., Sushma, Yanamandra, Saini, Neha, Chauhan, Pooja, Gill, Jasmeen, Rikhi, Deepika, Khadwal, Alka, Prakash, Gaurav, Lad, Deepesh, Suri, Vikas, Kumari, Savita, Varma, Neelam, and Varma, Subhash
- Subjects
KINASE inhibitors ,CHRONIC myeloid leukemia ,PATIENT compliance - Abstract
Purpose: The introduction of tyrosine kinase inhibitors has transformed the care of patients with chronic myeloid leukemia, with survival approaching that of healthy individuals. Current-day challenges in chronic myeloid leukemia care include adherence to tyrosine kinase inhibitor therapy. We studied adherence from resource-constrained settings and tried to analyze the factors responsible for nonadherence in these individuals. We also correlated adherence to current molecular status. Patients and Methods: This was a single-center, cross-sectional, observational study from north India. It consisted of a questionnaire-based survey in which a one-to-one interview technique was used by trained nursing staff administering the Modified Morisky Adherence Scale (MMAS-9) questionnaire. Adherence was also measured on the basis of physician's assessment. JMP 13.0.0 was used for statistical analysis. Results: A total of 333 patients with a median age of 42 years were included in the study. The median BCR-ABL/ABL ratio (IS) was 0.175 (0.0 to 98.0). The mean MMAS-9 score was 11 ± 2. Adherence was seen in 54.95% on the basis of MMAS-9, whereas physician's assessment reported adherence in 90.39% of patients. Using the χ
2 test, no relationship was found between the two assessment techniques. There was a significant relationship between major molecular response status and adherence by physician's assessment and MMAS-9 (P <.001). Bivariate analysis by logistic fit showed a good relation between the MMAS-9 score and the BCR-ABL/ABL ratio (IS), χ2 (1,220) = 135.45 (P <.001). On multivariate analysis, enrolment in the Novartis Oncology Access program (a patient assistance program) was significantly associated with adherence (P =.012). Conclusion: This study highlights the lack of adherence in real-world settings and the various factors responsible. Such studies are important from a public health services perspective in various settings around the world because they may lead to corrective action being taken at the institutional level. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
6. Ponatinib‐induced lamellar ichthyosis‐like eruption.
- Author
-
Thakur, Vishal, Malhotra, Pankaj, Lad, Deepesh, Chatterjee, Debajyoti, Vinay, Keshavamurthy, and Dogra, Sunil
- Subjects
ICHTHYOSIS ,PATHOLOGY ,CHRONIC myeloid leukemia - Abstract
Dear Editor, Tyrosine kinase inhibitors (TKI) have significantly improved the outcome and survival in patients of leukemia. However, these agents are frequently associated with mucocutaneous adverse effects including, but not limited to, cutaneous rash, xerosis, pruritus, alopecia, and stomatitis.[[1]] Herein, we report a case of generalized lamellar ichthyosis-like rash in the setting of ponatinib, a third-generation TKI used for treatment of chronic myeloid leukemia (CML). Phase 2 and 3 clinical trials have shown xerosis, pruritus, and rash to be the most common mucocutaneous adverse effects associated with ponatinib therapy.[3] Other reported cutaneous adverse effects of ponatinib include pityriasis rubra pilaris-like eruption, prominent folliculocentric seborrheic eruption, diffuse ichthyosiform changes, and ichthyosis vulgaris-like eruption.[3], [4], [5] To the best of our knowledge, this is the first report of ponatinib-induced lamellar ichthyosis-like eruption from India. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
7. Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study.
- Author
-
Goni, Deepak, Jain, Arihant, Singh, Charanpreet, Jindal, Nishant, Nampoothiri, Ram, Jandial, Aditya, Lad, Deepesh, Khadwal, Alka, Prakash, Gaurav, Naseem, Shano, Varma, Neelam, and Malhotra, Pankaj
- Subjects
- *
IMATINIB , *BLOOD cell count , *TERMINATION of treatment , *CHRONIC myeloid leukemia - Abstract
Background & objectives: Both innovator and generic imatinib are approved for the treatment of Chronic Myeloid Leukaemia-Chronic phase (CML-CP). Currently, there are no studies on the feasibility of treatment-free remission (TFR) with generic imatinib. This study attempted to determine the feasibility and efficacy of TFR in patients on generic Imatinib. Methods: In this single-centre prospective Generic Imatinib-Free Trial-in-CML-CP study, twenty six patients on generic imatinib for ≥3 yr and in sustained deep molecular response (BCR ABLIS ≤0.01% for more than two years) were included. After treatment discontinuation, patients were monitored with complete blood count and BCR ABLIS by real-time quantitative PCR monthly for one year and three monthly thereafter. Generic imatinib was restarted at single documented loss of major molecular response (BCR ABLIS>0.1%). Results: At a median follow up of 33 months (interquartile range 18.7-35), 42.3 per cent patients (n=11) continued to be in TFR. Estimated TFR at one year was 44 per cent. All patients restarted on generic imatinib regained major molecular response. On multivariate analysis, attainment of molecularly undetectable leukaemia (>MR5) prior to TFR was predictive of TFR [P=0.022, HR 0.284 (0.096-0.837)]. Interpretation & conclusions: The study adds to the growing literature that generic imatinib is effective and can be safely discontinued in CML-CP patients who are in deep molecular remission. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies.
- Author
-
Bhattacharjee, Urmimala, Jandial, Aditya, Singh, Charanpreet, Lekshmon, KS, Mishra, Kundan, Sandal, Rajeev, Nampoothiri, Ram, Naseem, Shano, Suri, Vanita, Jain, Arihant, Lad, Deepesh P., Prakash, Gaurav, Khadwal, Alka, and Malhotra, Pankaj
- Subjects
- *
UNPLANNED pregnancy , *PREGNANCY outcomes , *CHRONIC myeloid leukemia , *PROTEIN-tyrosine kinase inhibitors , *WOMEN patients , *CHRONIC leukemia - Abstract
Despite the general recommendation to avoid Tyrosine Kinase Inhibitors (TKIs) for Chronic Myeloid Leukemia (CML) during pregnancy, unplanned pregnancies still occur, particularly among female patients residing in low- and middle-income countries (LMICs). We aimed to investigate the outcomes of pregnancy, foetal development, and disease progression among female CML patients in chronic phase (CML-CP) undergoing TKI therapy who encountered unplanned pregnancies in a tertiary care hospital in northern India. We conducted a retrospective analysis of all pregnancies in female CML-CP between January 2002 and December 2022 at our hospital. Patients were included if they had a confirmed diagnosis of CML-CP, were receiving TKI therapy during conception, and had available medical records. We analysed the data on pregnancy outcomes, foetal development, and disease progression through a review of medical records. We identified 36 pregnancies in female CML-CP patients on TKI therapy during the study period, with 33 (91.7%) being unplanned. Sixteen pregnancies (48.5%) were conceived at less than major molecular remission (MMR) status. Twelve pregnancies (36.4%) were electively terminated, 4 (12.1%) had miscarriages, and, 17 (51.5%) pregnancies resulted in childbirth. Out of the 17 childbirths, 10 were full-term deliveries, and 7 were preterm deliveries. Twin pregnancies had a high incidence (18.2%). Among the 21 pregnancies that were not electively terminated, TKI was stopped at the first pregnancy detection in 14 pregnancies, while imatinib was continued throughout 7 pregnancies. Patients who discontinued TKI had a higher but statistically non-significant incidence of adverse pregnancy outcomes compared to those who continued imatinib throughout pregnancy (64.2% vs. 28.6%, p = 0.18). Additionally, the risk of long-term disease progression among patients who discontinued TKI during pregnancy and those who continued imatinib throughout pregnancy was 21.4% and 16.7% (p = 0.9), respectively. The risk of long-term disease progression was significantly increased in those persistently at less than MMR pre- and post-gestation (p = 0.0002). Our findings suggest that continuing imatinib therapy during pregnancy, may be a reasonable option for CML patients residing in low- and middle-income countries to reduce the risk of disease progression and adverse pregnancy outcomes. Patients persistently at less than MMR levels pre- and post-gestation should be closely monitored for the risk of long-term disease progression. Further studies with larger sample sizes are needed to confirm these results. • High incidence of unplanned pregnancies noted in female chronic myeloid leukaemia patients on tyrosine kinase inhibitors. • Continuing imatinib during pregnancy may be a reasonable option for CML patients residing in low-and-middle-income countries. • Long-term disease progression is higher in patients with poorly controlled CML who discontinue therapy during pregnancy. • Patients without major molecular remission pre-and post-gestation require close monitoring for long-term disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.